An Update from Regenx Biosciences and Voyager Therapeutics

Biosciences, LLC and Voyager Therapeutics today announced that they have entered into a license agreement for use of REGENX’s proprietary NAV® vectors for the development and commercialization of gene therapies to treat Amyotrophic Lateral Sclerosis (ALS), Friedreich’s ataxia (FA) and Huntington’s disease (HD).

  • Voyager acquires rights to REGENX’s proprietary NAV® vectors in multiple CNS disorders
  • Eighth third-party commercial license of REGENX’s NAV vectors since 2010
  • REGENX to receive undisclosed upfront payment, milestones and royalties in exchange for non-exclusive worldwide license